Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Oramed Pharmaceuticals is a clinical-stage biotechnology company developing oral drug delivery platforms, primarily focused on oral insulin (ORMD-0801) for diabetes treatment and oral GLP-1 therapies (ORMD-0901). The company operates through partnerships including a joint venture with Hefei Tianhui Incubator of Technologies (HTIT) for Chinese market development. With minimal revenue, negative operating cash flow, and a clinical pipeline dependent on regulatory milestones, the stock trades on binary clinical trial outcomes and partnership announcements rather than fundamental earnings.
Oramed operates a pre-revenue clinical development model, investing in Phase 3 trials for oral insulin and earlier-stage GLP-1 programs. The business model relies on achieving regulatory approvals to generate product revenue or securing strategic partnerships/licensing deals that provide upfront payments, milestone payments, and royalties. The oral delivery platform represents potential competitive advantage if clinical efficacy matches injectable alternatives, addressing patient compliance issues. Current cash burn is funded through equity raises and partnership capital, with monetization dependent on successful FDA/international regulatory approvals expected in 2027-2028 timeframe for lead programs.
Phase 3 clinical trial data readouts for ORMD-0801 oral insulin (efficacy vs. injectable insulin, safety profile)
FDA regulatory milestone announcements (IND approvals, breakthrough therapy designations, NDA submissions)
Partnership announcements or modifications to HTIT joint venture terms in China
Equity financing announcements and cash runway updates given negative operating cash flow
Competitive developments in oral insulin and GLP-1 markets from larger pharma competitors
Binary clinical trial risk - Phase 3 failure for ORMD-0801 would eliminate primary value driver with limited pipeline depth
Regulatory approval uncertainty for novel oral delivery platform requiring demonstration of bioequivalence to established injectable therapies
Competitive threat from oral semaglutide (Rybelsus) and other oral GLP-1 programs from well-capitalized competitors (Novo Nordisk, Eli Lilly)
Reimbursement risk - payers may not provide premium pricing for oral formulation vs. generic injectable insulin
Large pharmaceutical companies (Novo Nordisk, Sanofi, Eli Lilly) dominating diabetes market with established distribution and physician relationships
Multiple oral insulin programs in development by better-capitalized competitors could reach market first or demonstrate superior efficacy
Rapid innovation in diabetes care including continuous glucose monitors and automated insulin delivery systems potentially reducing oral insulin market opportunity
Cash burn of approximately $20-30M annually with current market cap of only $100M creates ongoing dilution risk through equity raises
Limited revenue generation ability before 2027-2028 regulatory approvals requires continued access to capital markets
Partnership dependency - HTIT joint venture terms and capital contributions critical to funding Chinese market development without further dilution
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital through equity markets and affect partnership deal flow from larger pharmaceutical companies reducing M&A activity.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (typical for pre-revenue biotech with 5-10 year monetization horizons). Higher rates also increase opportunity cost of capital, making speculative biotech investments less attractive relative to fixed income. Minimal direct business impact as company carries no debt, but equity financing becomes more expensive in high-rate environments.
Minimal direct credit exposure given zero debt and strong current ratio of 22.24. However, tightening credit conditions can reduce availability of venture debt or partnership financing from pharmaceutical companies facing their own financing constraints.
growth/speculative - Attracts biotech-focused investors willing to accept binary clinical trial risk for potential multi-bagger returns if oral insulin achieves approval. Recent 58.7% six-month return indicates momentum trading interest. Not suitable for value or income investors given pre-revenue status and no dividends. Typical holders include specialized healthcare hedge funds, retail biotech traders, and venture-stage life sciences investors.
high - Clinical-stage biotech with $100M market cap exhibits extreme volatility around trial data releases, regulatory announcements, and financing events. Low float and limited institutional coverage amplify price swings. Beta likely exceeds 2.0 relative to broader market.
